Bioinvent International AB
Records under this name other than the patents Bioinvent International AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 10 patents it holds.
Back to Bioinvent International AB
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,291,569 | Novel Antibodies and Nucleotide Sequences, and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 8,758,749 | Biological materials and uses thereof Lapsed on the fee record Ended Jun 24, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 24, 2026 | USPTO record |
| US 9,803,013 | Biological materials and uses thereof Lapsed on the fee record Ended Oct 31, 2025 · USPTO record | Lapsed on the fee record | Ended Oct 31, 2025 | USPTO record |
| US 10,351,970 | Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands Term ended Term ended Jul 12, 2024 · USPTO record | Term ended | Term ended Jul 12, 2024 | USPTO record |
| US 9,266,952 | Antibodies against ROR1 and uses thereof Lapsed on the fee record Ended Feb 23, 2024 · USPTO record | Lapsed on the fee record | Ended Feb 23, 2024 | USPTO record |
| US 9,150,647 | Biological inhibitors of ROR1 capable of inducing cell death Formerly held Lapsed on the fee record Ended Oct 6, 2023 · USPTO record | Lapsed on the fee record | Ended Oct 6, 2023 | USPTO record |
| US 7,943,744 | ICAM-1 binding antibodies Lapsed on the fee record Ended May 17, 2023 · USPTO record | Lapsed on the fee record | Ended May 17, 2023 | USPTO record |
| US 6,495,321 | Method for in vitro molecular evolution of protein function Formerly held Term ended Ended no later than Apr 6, 2020 · USPTO record | Term ended | Ended no later than Apr 6, 2020 | USPTO record |
| US 7,432,083 | Method for in vitro molecular evolution of protein function Term ended Term ended Jan 19, 2019 · USPTO record | Term ended | Term ended Jan 19, 2019 | USPTO record |
| US 7,153,655 | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence Lapsed on the fee record Ended Dec 26, 2018 · USPTO record | Lapsed on the fee record | Ended Dec 26, 2018 | USPTO record |